Discovery of ADDL-Targeting Small Molecule Drugs for Alzheimers Disease

Raymond   M.   Lowe; Grant   A.   Krafft; David      Summa; William   F.   Goure; Susan   M.   Catalano; Sue      Zhang; Hsiu-Mei      Wu; Lily      Ruslim-Litrus; Michele      McEntee; Gary   C.   Look; Catherine   M.   Hironaka; Lev      Igoudin; Walter   J.   Crosier; Jean-Claude   R.   Breach; Todd   R.   Pray; Diana   B.   Cherbavaz; Jasna      Jerecic

doi:10.2174/156720507783018271

Abstract

Amyloid β-derived diffusible ligands (ADDLs) comprise the neurotoxic subset of soluble Aβ1-42 oligomers, now widely considered to be the molecular cause of memory malfunction and neurodegeneration in Alzheimers disease (AD). We have developed a screening cascade which identifies small molecule modulators of ADDL-mediated neurotoxicity. The primary screen involves a fluorescence resonance energy transfer (FRET)-based assay which selects inhibitors of Aβ1-42 oligomer assembly. The identified hits were further characterized by assessing their ability to inhibit the assembly and binding of ADDLs to cultures of primary hippocampal neurons. This approach has led to the identification of a number of small molecules which inhibit ADDL assembly and their subsequent binding to neurons. Here we describe our small molecule discovery efforts to identify ADDL assembly blocker and ADDL binding inhibitors, and to transform validated hits into pre-clinical lead compounds.

Keywords: ADDL, Alzheimer, amyloid, assembly, drug, inhibitor, neuron, oligomer